Factors associated with the retention of secukinumab in patients with axial spondyloarthritis in real-world practice: results from a retrospective study (forsya)

HIGHLIGHTS

• who: Spondyloarthritis and collaborators from the treatment of patients with axSpA (radiographic (r-u00adaxSpA) and non-u00adradiographic (nr-u00adaxSpA)), Secukinumab has demonstrated significant long-u00ad term efficacy and safety versus placebo in patients with axSpA across various randomised clinical trials (RCTs).6, RCTs evaluate sophisticated outcome measures including MRI, health-u00adrelated quality of life with a stringent prospective, randomised and controlled, However, RCTs typically have a smaller and well-u00addefined study population. Data from RCTs may not fully mimic secukinumab treatment in a real-u00adworld setting because clinical trials are highly regulated and do not inevitably represent . . .
  

   

  

  If you want to have access to all the content you need to log in!

  Thanks :)

  Username or E-mail:

  If you don't have an account, you can create one here.